Semaglutide identity testing measures the whole mass of the molecule, usually by electrospray mass spectrometry. The found value is checked against the theoretical mass of semaglutide. How it runs on a column next to a reference is read alongside. A purity percentage alone cannot prove identity, because purity only says how much of one thing is present.
- A purity percentage is an area ratio from a chromatogram and carries no information about whether the main peak is semaglutide.
- Semaglutide's identity anchors are the molecular formula C187H291N45O59 and an average mass close to 4113.6 Da.
- Deconvoluted intact mass by electrospray ionization is the primary identity evidence on a research certificate.
- Retention-time agreement with a reference standard supports identity only in combination with mass data, because unrelated compounds can co-elute.
- A certificate line reading "conforms" without printed theoretical and found mass values is an assertion, and an assertion is not a measurement.
What this guide covers
Think of it like a photo ID at an airport. A crisp photo shows the card is in good shape. The name and face matching the traveler is what tells you who is standing there, and mass spectrometry is that name check.
A certificate that reports 99% purity has told you almost nothing about identity. The purity figure comes from a chromatogram: the material is run through a reverse-phase HPLC column, everything that elutes is detected, and the main peak's area is divided by the total. The result is a statement about homogeneity. It says one substance dominates the vial. It does not say which substance that is.
The distinction sounds academic until you consider what an area percentage looks like for the wrong compound. A vial of the wrong peptide, synthesized competently, shows a clean single peak and a high purity number. So does an undegraded small molecule that has no business being there. The chromatogram cannot tell the difference, because area percent presumes the analyte and then measures how much of the signal it accounts for.
Identity testing exists to check the presumption. It asks a separate question with separate instruments: is the substance in this vial the molecule the label claims? For a peptide of semaglutide's size the primary answer comes from mass spectrometry, with chromatographic behavior as supporting evidence, and a certificate worth reading reports both. This guide covers what those measurements prove, where each one runs out, and how to read the identity block on a certificate without taking the word "conforms" on faith.
- Appearance: consistent with a peptide, nothing more
- Retention time vs reference: supporting, never sufficient
- Deconvoluted intact mass: the primary evidence
- Tandem MS and peptide mapping: sequence-level proof, rarely routine
- Lot number match: what ties the paper to the vial
Which molecule do the identity tests have to match?
Semaglutide is an analog of human GLP-1(7-37), a 31-residue peptide, carrying three deliberate changes. Position 8 holds α-aminoisobutyric acid (Aib), a non-coded residue that resists enzymatic cleavage. Position 34 is arginine in place of the native lysine, which leaves lysine 26 as the only lysine in the chain. That lysine carries the third change: a C18 fatty diacid, octadecanedioic acid, attached through a linker built from one γ-glutamate and two short PEG-like spacer units.
The arginine substitution matters more for identity work than it first appears. With one lysine in the sequence, the fatty diacid can only sit in one place, so the finished molecule has a single defined structure rather than a family of positional isomers. Identity testing gets to aim at one target.
That target has a molecular formula of C187H291N45O59 and an average molecular mass close to 4113.6 Da, figures carried on the compound's public chemistry records. Every identity measurement on a certificate is a comparison against these anchors. The formula fixes what the intact mass should be. The linker and the lipid chain change how the molecule behaves on a reverse-phase column relative to the unmodified peptide. A laboratory receiving material against the Semaglutide product record is checking observed numbers against these expectations, and the tests below are how the checking is done.
What does mass spectrometry prove about semaglutide?
The workhorse measurement is intact mass by electrospray ionization. The dissolved peptide is sprayed into the instrument, picks up several protons, and appears in the spectrum as a set of multiply charged ions. Software deconvolutes the series back to a neutral mass, and the certificate reports that number against theory. For a molecule of this size a modern time-of-flight or Orbitrap instrument measures well within one dalton, and agreement between found and theoretical mass at that tolerance is strong evidence that the elemental composition is right.
Strong evidence, with defined limits. An intact mass matches a formula, and a formula is not a structure. Any rearrangement of the same atoms is invisible to the measurement. Leucine and isoleucine weigh exactly the same. A glutamine-for-lysine error changes the mass by 0.036 Da, which a routine instrument will not resolve at 4.1 kDa. Deamidation, one of the standard degradation routes for peptides in this family, adds just under one dalton and needs good resolution to separate from the parent.
Two tiers of evidence sit above intact mass when a supplier or an independent laboratory wants a stronger case. Tandem MS fragments the molecule and reads sequence information from the pieces. Peptide mapping digests it enzymatically and confirms that the fragment set matches prediction. Both are routine in pharmaceutical characterization and rare on a research certificate, which is worth knowing so that their absence reads as normal rather than as concealment. MALDI-TOF appears on some certificates instead of electrospray; it reports a singly charged ion with somewhat looser accuracy at this mass, and it is acceptable evidence when the tolerance is stated.
How does chromatography support the mass data?
The second identity element on most certificates is chromatographic: the material's retention time on a reverse-phase column, compared with a semaglutide reference standard run under the same conditions. Pharmacopeial identity tests for peptides have leaned on retention-time agreement for decades, and the logic is plain. Retention on a reverse-phase column integrates hydrophobicity, conformation and the behavior of the fatty diacid chain. A molecule matching the reference across that combination is behaving like semaglutide.
On its own the measurement is weak. A retention time is one number, columns and gradients vary, and unrelated compounds can co-elute under any single condition set. What makes it useful is coincidence with the mass data. For a vial to pass both checks wrongly, it would have to contain a compound with the same intact mass and the same retention behavior, and the population of plausible candidates satisfying both is very small. Orthogonal methods with different failure modes is the principle behind identity specifications in the ICH quality guidance for biological molecules, and it applies unchanged at research grade.
The same run usually supplies the purity figure, which is convenient and is also the source of the confusion this guide opened with. One chromatogram, two claims: the retention time supports identity, the area percent describes homogeneity. Keeping those two claims separate is most of what certificate literacy amounts to.
Which identity evidence is strongest?
| Evidence | What it establishes | Where it runs out |
|---|---|---|
| Appearance (white to off-white lyophilized solid) | The presentation is consistent with a peptide | Says nothing about which peptide |
| RP-HPLC retention vs reference standard | Behavior matches semaglutide under one condition set | Co-elution is possible; no structural information |
| Intact mass, electrospray, deconvoluted | Elemental composition consistent with C187H291N45O59 | Blind to residue order and near-isobaric errors |
| Tandem MS fragmentation | Sequence-level confirmation of stretches of the chain | Rare on research certificates; interpretation takes skill |
| Peptide mapping after enzymatic digestion | Fragment set matches the defined structure | Same rarity; method setup is compound-specific |
| Amino acid analysis | Residue composition and net peptide content | No sequence order; non-coded residues need care |
No single row settles identity. A certificate reporting appearance, retention agreement and a deconvoluted intact mass has made a cumulative case that is adequate for most laboratory purposes. A certificate reporting appearance and purity alone has made no identity case at all. The middle of the table is where a competent research supplier operates; the bottom rows belong to pharmaceutical characterization campaigns and to disputes, when a result matters enough to pay for sequence-level proof.
Reading the identity block, step by step
Here are the checks, in the order a reviewer applies them.
- The mass entry should be two printed numbers. Theoretical and found, with the technique named beside them. A line reading "Identity: conforms" with no values is an assertion, and the entire point of a certificate is to replace assertion with measurement. Discount it as evidence, whatever the letterhead.
- The found value should look measured. Instruments scatter. A found mass reproduced to two decimals, exactly matching theory, across every lot a supplier has ever shipped is a template, and templates are the failure mode independent testing keeps catching in the research market.
- Average and monoisotopic must not be mixed. Theory can be quoted either way, and the two conventions differ by roughly two and a half daltons for a molecule of this size. A certificate comparing a monoisotopic theoretical value against an average found value manufactures a discrepancy, and one doing the reverse hides one. The document should say which convention it uses.
- The lot number ties everything together. The certificate describes a lot, the vial label names a lot, and the two must match, with the analytical report reflecting a sample drawn from that specific lot.
- Purity sits on its own line and answers its own question: method stated, area percent given, chromatogram attached if the supplier is serious. What the number means, and what else a complete quality file contains, is covered in the quality standard. What happens to the material after it passes review is a storage question, covered in the storage and stability guide.
Red flags in a semaglutide identity block
- "Identity: conforms" printed with no theoretical or found value.
- A certificate that reports appearance and purity and nothing else. That makes no identity case at all.
- A found mass that matches theory to two decimals on every lot the supplier has shipped.
- No statement of whether the masses are average or monoisotopic.
- A retention time with no reference standard run under the same conditions.
- A lot number on the certificate that differs from the one on the vial.
What is the regulatory status of semaglutide?
Semaglutide is a GLP-1 receptor agonist. FDA-approved prescription medicines containing semaglutide exist, manufactured under pharmaceutical quality systems that a research-chemical supply chain does not replicate.
The FDA declared the semaglutide injection shortage resolved on February 21, 2025. With the shortage over, the agency's enforcement discretion for compounded semaglutide ended on April 22, 2025 for 503A compounding pharmacies and May 22, 2025 for 503B outsourcing facilities. Research-grade material has never been a lawful route to human use at any point in that timeline.
Status verified August 25, 2026.
FOR LABORATORY AND IN-VITRO RESEARCH USE ONLY. NOT FOR HUMAN OR ANIMAL CONSUMPTION. NOT FOR PERSONAL, MEDICAL, DIAGNOSTIC, THERAPEUTIC, OR RECREATIONAL USE.
Bottom line
A purity figure says one substance dominates the vial. It does not say the substance is semaglutide. Identity rests on a deconvoluted intact mass checked against C187H291N45O59 (about 4113.6 Da), read together with retention agreement against a reference standard. Expect both numbers printed, the method and mass convention named, and a lot number that matches the vial.
What is Semaglutide studied for?
Published research on Semaglutide investigates the areas below, which is a different question from what Semaglutide will do for anyone, a claim about a living system that nothing on this site is sold for.
What it is. A peptide that works on the GLP-1 receptor.
What the research looks at. One of the most heavily published peptides in metabolic research, with a large registered clinical record. Approved medicines containing it exist under their own brand names.
How it is thought to work. A copy of the body’s own GLP-1, changed so it lasts far longer. Two changes do that: a fatty acid chain that lets it ride on albumin in the blood, and a swapped building block that stops the DPP-4 enzyme cutting it up. Those two edits are why it stays around for days where natural GLP-1 lasts minutes.
What is not established. What is sold here is a research chemical, not a drug product. Listing it is not an approval, and not a claim that it is equivalent to, as safe as, or a fit substitute for any approved medicine.
The full record, including the certificate for the lot in stock, is on the Semaglutide product page.
Common questions
Can a vial show 99% purity and still not be semaglutide?
What mass should a semaglutide certificate report?
Is a retention-time match enough to confirm identity?
Is MALDI-TOF acceptable instead of electrospray on a certificate?
Does a passing certificate guarantee what is in my specific vial?
Published certificates for Semaglutide
Every figure below is read from a report the laboratory issued for that lot; each page carries the PDF and the lab's own verification link.
More documentation guides
Sources
- PubChem, semaglutide compound record. Molecular formula C187H291N45O59 and average molecular mass near 4113.6 Da; the theoretical anchors every identity measurement is compared against.
- Lau et al., Journal of Medicinal Chemistry, 2015. The semaglutide discovery paper; supports the Aib8 and Arg34 substitutions, the single-lysine design, and the C18 fatty diacid attachment at lysine 26.
- ICH Q6B, specifications for biotechnological and biological products. The principle that identity is established by specific, orthogonal methods rather than by any single measurement.
- FDA drug shortage determination for semaglutide injection, 21 February 2025. Supports the shortage-resolution date and the 22 April and 22 May 2025 compounding discretion end dates.
